Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin-BEAM for Low-Grade B-Cell Lymphoma
NCT00138086Phase 2Completed
- Sponsor
- Lymphoma Study Association
- Start
- Mar 2005
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of ibritumomab tiuxetan in B cell lymphoma, sponsored by Lymphoma Study Association. Started Mar 2005; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT00138086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00138086.